The lipid droplet in cancer : From being a tumor-supporting hallmark to clinical therapy
© 2024 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd..
INTRODUCTION: Abnormal lipid metabolism, one of the hallmarks in cancer, has gradually emerged as a novel target for cancer treatment. As organelles that store and release excess lipids, lipid droplets (LDs) resemble "gears" and facilitate cancer development in the body.
AIM: This review discusses the life cycle of LDs, the relationship between abnormal LDs and cancer hallmarks, and the application of LDs in theragnostic and clinical contexts to provide a contemporary understanding of the role of LDs in cancer.
METHODS: A systematic literature search was conducted in PubMed and SPORTDiscus. Retrieve and summarize clinical trials of drugs that target proteins associated with LD formation using the Clinical Trials website. Create a schematic diagram of lipid droplets in the tumor microenvironment using Adobe Illustrator.
CONCLUSION: As one of the top ten hallmarks of cancer, abnormal lipid metabolism caused by excessive generation of LDs interrelates with other hallmarks. The crosstalk between excessive LDs and intracellular free fatty acids (FFAs) promotes an inflammatory environment that supports tumor growth. Moreover, LDs contribute to cancer metastasis and cell death resistance in vivo. Statins, as HMGCR inhibitors, are promising to be the pioneering commercially available anti-cancer drugs that target LD formation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:240 |
|---|---|
| Enthalten in: |
Acta physiologica (Oxford, England) - 240(2024), 3 vom: 28. Feb., Seite e14087 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cui, Yingfang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer treatment |
|---|
| Anmerkungen: |
Date Completed 26.02.2024 Date Revised 26.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/apha.14087 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367378868 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367378868 | ||
| 003 | DE-627 | ||
| 005 | 20240229154942.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apha.14087 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1306.xml |
| 035 | |a (DE-627)NLM367378868 | ||
| 035 | |a (NLM)38247395 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cui, Yingfang |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The lipid droplet in cancer |b From being a tumor-supporting hallmark to clinical therapy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2024 | ||
| 500 | |a Date Revised 26.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd. | ||
| 520 | |a INTRODUCTION: Abnormal lipid metabolism, one of the hallmarks in cancer, has gradually emerged as a novel target for cancer treatment. As organelles that store and release excess lipids, lipid droplets (LDs) resemble "gears" and facilitate cancer development in the body | ||
| 520 | |a AIM: This review discusses the life cycle of LDs, the relationship between abnormal LDs and cancer hallmarks, and the application of LDs in theragnostic and clinical contexts to provide a contemporary understanding of the role of LDs in cancer | ||
| 520 | |a METHODS: A systematic literature search was conducted in PubMed and SPORTDiscus. Retrieve and summarize clinical trials of drugs that target proteins associated with LD formation using the Clinical Trials website. Create a schematic diagram of lipid droplets in the tumor microenvironment using Adobe Illustrator | ||
| 520 | |a CONCLUSION: As one of the top ten hallmarks of cancer, abnormal lipid metabolism caused by excessive generation of LDs interrelates with other hallmarks. The crosstalk between excessive LDs and intracellular free fatty acids (FFAs) promotes an inflammatory environment that supports tumor growth. Moreover, LDs contribute to cancer metastasis and cell death resistance in vivo. Statins, as HMGCR inhibitors, are promising to be the pioneering commercially available anti-cancer drugs that target LD formation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a cancer treatment | |
| 650 | 4 | |a lipid droplet | |
| 650 | 4 | |a lipid metabolism | |
| 650 | 4 | |a metabolic enzymes | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Man, Shuli |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Jiejing |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Lanping |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Luqi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Changxiao |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Wenyuan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta physiologica (Oxford, England) |d 2006 |g 240(2024), 3 vom: 28. Feb., Seite e14087 |w (DE-627)NLM160895634 |x 1748-1716 |7 nnns |
| 773 | 1 | 8 | |g volume:240 |g year:2024 |g number:3 |g day:28 |g month:02 |g pages:e14087 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apha.14087 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 240 |j 2024 |e 3 |b 28 |c 02 |h e14087 | ||